TY - JOUR AU - Bellissimo, S. AU - Ferrucci, M.G. AU - Gallo, A. AU - Stisi, S. PY - 2007/09/30 Y2 - 2024/03/29 TI - Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis JF - Reumatismo JA - Reumatismo VL - 59 IS - 3 SE - Case Reports DO - 10.4081/reumatismo.2007.240 UR - https://www.reumatismo.org/reuma/article/view/reumatismo.2007.240 SP - 240-243 AB - Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-α, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis. ER -